Scientists have discovered that some people have a gene variation that not only inhibits some cancer treatments but also increases the risk of cancer recurrence.
The new funding is from Team Verrico which supports cutting edge research into new or improved treatments for cancer. The volunteer charity is named after Anna Verrico, a mum of two who died from triple negative breast cancer in 2013. The national charity also supports poorly parents with second opinions in Harley Street and offers counselling to families affected by cancer.
The funding will explore the relationship between receptors on the surface of cells called ADRB2, and cancer. When someone is diagnosed with breast cancer the resulting stress releases adrenaline and noradrenaline hormones which bind to ADRB2 on the surface of the cancer cells. This can stop some cancer treatments, including chemotherapy, from working.
The university’s team comprises Dr Melanie Flint, Reader in Cancer Biology; Dr Caroline Garrett, Human Tissue Governance Manager; Dr Greg Scutt, Principal Lecturer; and Dr Andrew Overall, Senior Lecturer, all from the School of Pharmacy and Biomolecular Sciences.